Press release
Cutaneous Lupus Erythematosus Pipeline: Over 8 Leading Companies Driving Innovation with Promising Therapeutic Developments | DelveInsight
Cutaneous Lupus Erythematosus Pipeline
DelveInsight's "Cutaneous Lupus Erythematosus Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Cutaneous Lupus Erythematosus market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging Cutaneous Lupus Erythematosus drugs, the Cutaneous Lupus Erythematosus pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Cutaneous Lupus Erythematosus Pipeline Report
• DelveInsight's Cutaneous Lupus Erythematosus Pipeline analysis depicts a robust space with 8+ active players working to develop 10+ pipeline drugs for Cutaneous Lupus Erythematosus treatment.
• The leading Cutaneous Lupus Erythematosus companies include Hoth Therapeutics, Centessa Pharmaceuticals, Bristol-Myers Squibb, Biogen, Sanofi, Zylo Therapeutics, Gilead Sciences, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Horizon Therapeutics, and others are evaluating their lead assets to improve the Cutaneous Lupus Erythematosus treatment landscape.
• Key Cutaneous Lupus Erythematosus pipeline therapies in various stages of development include HT-005, CBS004, BMS-986256, M5049, BMS-986165 (deucravacitinib), BIIB059, SAR443122, and others.
• In November 2024, ImmuneSensor Therapeutics announced that the FDA granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to its lead drug candidate, IMSB301, for treating cGAS-driven Type I interferonopathy, including Aicardi-Goutières Syndrome (AGS). IMSB301, a novel oral cGAS inhibitor, is also being developed for inflammatory and autoimmune diseases like systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).
• In Oct 2024, Cullinan Therapeutics received FDA clearance for its Investigational New Drug (IND) application for CLN-978, allowing it to proceed with a global Phase 1 clinical trial in patients with moderate to severe systemic lupus erythematosus (SLE).
• In August 2024, the Lupus Research Alliance (LRA), founder and administrator of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), announced an expanded partnership with the U.S. Food and Drug Administration (FDA) during the Consortium's first anniversary meeting, now including the Center for Biologics Evaluation and Research (CBER).
• In May 2024, the FDA approved a 200 mg subcutaneous injection of belimumab (Benlysta; GSK) for patients aged 5 and older with active systemic lupus erythematosus (SLE) who are receiving current therapy. This approval allows pediatric patients to receive treatment at home.
Request a sample and discover the recent breakthroughs happening in the Cutaneous Lupus Erythematosus pipeline landscape @ https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-cle-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Cutaneous Lupus Erythematosus Overview
Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin condition that significantly affects patients' quality of life. It can occur independently or as part of Systemic Lupus Erythematosus (SLE)-a more severe, multi-organ autoimmune disorder. Notably, individuals initially diagnosed with CLE may later develop systemic symptoms indicative of SLE.
CLE is classified into three major subtypes-acute (ACLE), subacute (SCLE), and chronic (CCLE)-based on the appearance and histology of skin lesions. Chronic CLE (CCLE) accounts for nearly 80% of cases, with Discoid Lupus Erythematosus (DLE) being the most common subtype. Each subtype varies not only in clinical features but also in its association with systemic lupus.
ACLE, often marked by the classic "butterfly rash", is almost always linked with systemic disease. In contrast, DLE typically presents as scarring and pigmented lesions on the head and neck. However, a subset of DLE patients may experience more widespread lesions across the body, and 10-20% may progress to SLE, with generalized DLE cases carrying a higher risk of systemic involvement.
Find out more about Cutaneous Lupus Erythematosus medication @ https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-cle-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Cutaneous Lupus Erythematosus Treatment Analysis: Drug Profile
BIIB059: Biogen
BIIB059 is a fully humanized IgG1 monoclonal antibody developed by Biogen for the treatment of Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE). It targets BDCA2, a receptor found exclusively on plasmacytoid dendritic cells (pDCs). By binding to BDCA2, BIIB059 reduces the production of inflammatory cytokines-especially type I interferons (IFN-I)-which are believed to be key drivers in lupus pathogenesis.
Key Cutaneous Lupus Erythematosus Therapies and Companies
• BIIB059: Biogen
• Litifilimab: Biogen
• Daxdilimab: Horizon Therapeutics
• SOTYKTU (deucravacitinib): Bristol-Myers Squibb
Learn more about the novel and emerging Cutaneous Lupus Erythematosus pipeline therapies @ https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-cle-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Cutaneous Lupus Erythematosus Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule
Scope of the Cutaneous Lupus Erythematosus Pipeline Report
• Coverage: Global
• Key Cutaneous Lupus Erythematosus Companies: Hoth Therapeutics, Centessa Pharmaceuticals, Bristol-Myers Squibb, Biogen, Sanofi, Zylo Therapeutics, Gilead Sciences, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Horizon Therapeutics, and others.
• Key Cutaneous Lupus Erythematosus Pipeline Therapies: HT-005, CBS004, BMS-986256, M5049, BMS-986165 (deucravacitinib), BIIB059, SAR443122, and others.
Dive deep into rich insights for drugs used for Cutaneous Lupus Erythematosus treatment; visit @ https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-cle-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Cutaneous Lupus Erythematosus Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Cutaneous Lupus Erythematosus Pipeline Therapeutics
6. Cutaneous Lupus Erythematosus Pipeline: Late-Stage Products (Phase III)
7. Cutaneous Lupus Erythematosus Pipeline: Late-Stage Products (Phase III)
8. Cutaneous Lupus Erythematosus Pipeline: Mid-Stage Products (Phase II)
9. Cutaneous Lupus Erythematosus Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cutaneous Lupus Erythematosus Pipeline: Over 8 Leading Companies Driving Innovation with Promising Therapeutic Developments | DelveInsight here
News-ID: 3956481 • Views: …
More Releases from DelveInsight
Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modu …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2025" explores over 10+ therapies in development for insulin resistance, a metabolic condition strongly linked to type 2 diabetes, obesity, and cardiovascular disease. Despite lifestyle modification and insulin-sensitizing drugs like metformin being mainstays of management, many patients continue to face poor glycemic control and associated complications, underscoring the need for more effective insulin resistance treatments.
The insulin resistance pipeline is broadening with next-generation therapies targeting…
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, an …
DelveInsight's "Uveal Melanoma - Pipeline Insight, 2025" explores over 30+ therapies in development for uveal melanoma, a rare and aggressive intraocular malignancy with high metastatic potential, most commonly to the liver. Despite surgery and radiotherapy being standards for localized disease, patients with metastatic uveal melanoma face limited systemic treatment options, creating significant unmet needs in the uveal melanoma treatment landscape.
The uveal melanoma pipeline is diversifying with next-generation targeted therapies, including…
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shap …
DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer disease symptoms such as abdominal pain, bloating, nausea, and gastrointestinal bleeding. Despite widespread use of existing peptic ulcer disease treatments, including proton pump inhibitors, H2 blockers, and antibiotics for H. pylori eradication, patients with recurrent or complicated peptic ulcers continue to face significant unmet needs,…
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trial …
DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a severe and recurring complication of sickle cell disease. Despite current standards of care, including hydroxyurea, patients continue to experience frequent vaso occlusive sickle cell crisis, underscoring the urgent need for effective interventions in sickle cell anemia vaso occlusive crisis treatment.
The VOC pipeline is diversifying with…
More Releases for Lupus
Cutaneous Lupus Erythematosus (CLE) Market
Introduction
Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disorder, often associated with systemic lupus erythematosus (SLE), that presents as inflammation, rashes, and photosensitivity. While CLE is rarely fatal, it significantly affects patients' physical and emotional well-being, often leading to scarring, disfigurement, and social stigma.
Over the past decade, the market for CLE therapies has gained global importance as research into autoimmunity has accelerated and biologic therapies have transformed dermatology. Rising…
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Cutaneous Lupus Erythematosus (CLE) Market
Market Overview:
The Global Cutaneous Lupus Erythematosus (CLE) Market is forecasted to achieve a High CAGR during the period 2023-2030. CLE encompasses a spectrum of dermatological symptoms that may precede or accompany systemic lupus erythematosus (SLE), an autoimmune condition impacting multiple organs. Timely diagnosis and treatment of CLE can prevent the onset of severe systemic symptoms.
Market Dynamics:
Drivers:
Rise in Clinical Studies: Technological advancements leading to faster and accurate diagnosis have spurred additional…
Lupus Nephritis Treatment Market 2030
Global Lupus Nephritis Treatment market is expected to be worth roughly USD 8,048 million by 2030, growing at a CAGR of 7.3% during the forthcoming period of 2022-2030, according to Ameco Research
Lupus nephritis is one of the most rapidly spreading diseases over the globe. The increasing frequency of lupus nephritis and consumer awareness has fuelled the worldwide lupus nephritis treatment market. Another crucial factor driving the pace of growth of…
Lupus Erythematosus Market -API Insights, 2017
Summary
Orbis Research Present “Lupus Erythematosus-API Insights, 2017”
Description
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage…
Global Systemic Lupus Erythematosus and Lupus Nephritis Market to Display 10.6% …
"The Report PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz has announced the addition of a new report, titled “PharmaPoint: Systemic Lupus Erythematosus And Lupus Nephritis - Global Drug Forecast And Market Analysis To 2025,” to its expanding repository of research reports. The market…
